Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and … Read more
Embla Medical hf (EMBLA) - Net Assets
Latest net assets as of December 2025: Dkr893.85 Million DKK
Based on the latest financial reports, Embla Medical hf (EMBLA) has net assets worth Dkr893.85 Million DKK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr1.74 Billion) and total liabilities (Dkr848.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr893.85 Million |
| % of Total Assets | 51.3% |
| Annual Growth Rate | 9.14% |
| 5-Year Change | 42.65% |
| 10-Year Change | N/A |
| Growth Volatility | 4.34 |
Embla Medical hf - Net Assets Trend (2020–2025)
This chart illustrates how Embla Medical hf's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Embla Medical hf (2020–2025)
The table below shows the annual net assets of Embla Medical hf from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr893.85 Million | +14.49% |
| 2024-12-31 | Dkr780.70 Million | +10.74% |
| 2023-12-31 | Dkr705.01 Million | +10.94% |
| 2022-12-31 | Dkr635.51 Million | +1.42% |
| 2021-12-31 | Dkr626.60 Million | +8.56% |
| 2020-12-31 | Dkr577.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Embla Medical hf's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 58.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr840.74 Million | 94.61% |
| Common Stock | Dkr4.83 Million | 0.54% |
| Other Comprehensive Income | Dkr-50.38 Million | -5.67% |
| Other Components | Dkr93.43 Million | 10.51% |
| Total Equity | Dkr888.61 Million | 100.00% |
Embla Medical hf Competitors by Market Cap
The table below lists competitors of Embla Medical hf ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
$608.05 Million |
|
LT Foods Limited
NSE:LTFOODS
|
$608.17 Million |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
$608.29 Million |
|
Rupert Resources Ltd
OTCQX:RUPRF
|
$608.42 Million |
|
Xvivo Perfusion AB (publ)
PINK:XVIPF
|
$607.94 Million |
|
Hunan New Wellful Co Ltd
SHG:600975
|
$607.92 Million |
|
Pagerduty Inc
NYSE:PD
|
$607.53 Million |
|
EFORT Intelligent Equipment Co Ltd
SHG:688165
|
$607.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Embla Medical hf's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 777,186,000 to 888,608,707, a change of 111,422,707 (14.3%).
- Net income of 86,467,812 contributed positively to equity growth.
- Share repurchases of 10,119,522 reduced equity.
- Other comprehensive income decreased equity by 50,382,987.
- Other factors increased equity by 85,457,404.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr86.47 Million | +9.73% |
| Share Repurchases | Dkr10.12 Million | -1.14% |
| Other Comprehensive Income | Dkr-50.38 Million | -5.67% |
| Other Changes | Dkr85.46 Million | +9.62% |
| Total Change | Dkr- | 14.34% |
Book Value vs Market Value Analysis
This analysis compares Embla Medical hf's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 20.13x to 13.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Dkr1.36 | Dkr27.30 | x |
| 2021-12-31 | Dkr1.47 | Dkr27.30 | x |
| 2022-12-31 | Dkr1.52 | Dkr27.30 | x |
| 2023-12-31 | Dkr1.67 | Dkr27.30 | x |
| 2024-12-31 | Dkr1.82 | Dkr27.30 | x |
| 2025-12-31 | Dkr2.08 | Dkr27.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Embla Medical hf utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.73%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.97%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.96x
- Recent ROE (9.73%) is above the historical average (7.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 1.09% | 0.99% | 0.52x | 2.12x | Dkr-51.04 Million |
| 2021 | 10.30% | 8.90% | 0.58x | 2.01x | Dkr1.84 Million |
| 2022 | 6.69% | 5.92% | 0.54x | 2.08x | Dkr-21.06 Million |
| 2023 | 8.32% | 7.31% | 0.58x | 1.97x | Dkr-11.80 Million |
| 2024 | 8.79% | 7.99% | 0.56x | 1.98x | Dkr-9.44 Million |
| 2025 | 9.73% | 8.97% | 0.55x | 1.96x | Dkr-2.39 Million |
Industry Comparison
This section compares Embla Medical hf's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $41,799,090
- Average return on equity (ROE) among peers: -3.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Embla Medical hf (EMBLA) | Dkr893.85 Million | 1.09% | 0.95x | $608.03 Million |
| ChemoMetec A/S (CHEMM) | $-10.06 Million | 0.00% | 0.00x | $929.50 Million |
| Scandinavian Medical Solutions AS (SMSMED) | $74.45 Million | 16.42% | 1.20x | $4.62K |
| ViroGates A/S (VIRO) | $61.01 Million | -27.84% | 0.04x | $5.23 Million |